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Sir,
Antimicrobial resistance is a serious and growing threat for 
global public health. In the European Union, Iceland and 
Norway, infections caused by antibiotic-resistant organisms 
are estimated to be responsible of 25,000 deaths per year [1].
A Swiss expert group on infectious diseases and hospital 
hygiene (Swissnoso) estimates that approximately 70,000 
nosocomial infections occurs yearly, among which, nearly 
2.9% end fatally for the patients [2]. In addition, attribut-
able mortality to multidrug-resistant bacteria, mostly Gram-
negatives, has been recently reported from Switzerland [3].
The most clinically-signiﬁcant and emerging resistant 
determinants are: (1) the extended-spectrum β-lactamases 
(ESBL) that confer resistance to all β-lactams except cepha-
mycins and carbapenems, (2) the carbapenemases that confer 
resistance to virtually all β-lactams, and (3) the 16S rRNA 
methylases that confer resistance to all aminoglycosides by 
methylation of the aminoglycosides target, namely the 16S 
ribosomal RNA.
We report here the colonization/infection of a patient 
hospitalized in India with six unrelated multidrug-resistant 
Gram-negative isolates who was transferred to Switzerland.
In November 2018, a 47-year-old man was repatriated 
from India to the tertiary care cantonal hospital of Aarau, 
Switzerland, after 2 weeks of hospitalization in three Indian 
hospitals (Goa region) for venous thrombosis, followed by 
severe nephropathy, likely related to rhabdomyolyses due 
to immobilization. Upon admission in Switzerland, he pre-
sented an acute kidney failure and was admitted for haemodi-
alysis. He had multiple abscesses (lateral thoraces, abdomen, 
gluteal and rectal), likely caused by traumatic immobilisa-
tion and/or septic thrombosis, which were debrided at the 
Aarau hospital.
As any patient having been hospitalized abroad, he was 
screened at the entrance for methicillin-resistant Staphylo-
coccus aureus (MRSA), vancomycin-resistant Enterococci
(VRE), extended-spectrum β-lactamase (ESBL)-producing 
and carbapenem-resistant Gram-negative bacteria. Urine, 
faeces and a pooled swab from nose, throat, axilla and groin 
were withdrawn and sent for screening of ESBL produc-
tion on CHROMagar Orientation (CHROMagar TM), for 
carbapenem resistance on CHROMagar mSuperCARBA, 
for MRSA on CHROMagar MRSA and for VRE on CHRO-
Magar VRE plates. No growth was observed on MRSA 
and VRE plates. However, diﬀerent colony types grew on 
the ESBL as well as on the carbapenem-resistant screen-
ing plates. A total of six multidrug-resistant Gram-negative 
bacterial isolates were obtained, being either colonizing 
or infecting agents (Table 1). Antimicrobial susceptibil-
ity testing was performed by disk diﬀusion assay (Sanoﬁ-
diagnostic Pasteur, France), gradient strips (bioMérieux, 
Lioﬁlchem), and broth dilution techniques were used to 
assess minimal inhibitory concentrations (MIC). EUCAST 
guidelines were used to interpret antimicrobial susceptibility 
[4]. Pan-resistant Escherichia coli, Klebsiella pneumoniae,
Enterobacter cloacae, Providencia rettgeri, Acinetobacter 
baumannii and Pseudomonas aeruginosa were found. All
isolates but K. pneumoniae, showed resistance to ertapenem,
and resistance or intermediate susceptibility to meropenem 
and imipenem. Additionally, all isolates showed resistance 
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to expanded-spectrum cephalosporins (ceftazidime, cefo-
taxime, cefepime), with the exception of the P. rettgeri and 
P. aeruginosa isolates that were of intermediate suscepti-
bility and susceptible to cefepime, respectively. The Rapid 
Carba NP test for Enterobacterales [5] and P. aeruginosa 
[6] and the CarbAcineto NP test for A. baumannii [7] were 
performed to detect carbapenemase activities. All isolates 
except the K. pneumoniae isolate gave positive results. PCR 
ampliﬁcation followed by sequencing identiﬁed production 
of carbapenemases in all those isolates, being either NDM- 
or VIM-type metallo-β-lactamases (Table 1). All strains 
remained susceptible to colistin according to the results of 
Rapid Polymyxin NP test [8], except the P. rettgeri isolate, 
that bacterial species being naturally resistant to polymyxins.
In addition, three isolates (E. coli, K. pneumoniae, E. 
cloacae) exhibited a synergy between clavulanic acid and 
aztreonam and/or cefepime. Results of the Rapid ESBL NP 
test [9] together with PCR ampliﬁcation and sequencing 
showed that these isolates produced an ESBL of CTX-M 
type (Table 1). Only P. rettgeri showed a restoration of the 
susceptibility to ceftazidime and cefotaxime in the presence 
of cloxacillin, suggesting the additional role of the overex-
pression of a cephalosporinase in the susceptibility pattern, 
i.e., the resistance to expanded-spectrum cephalosporins. 
PCR amplification revealed the presence of a plasmid-
encoded cephalosporinase blaCMY gene in that latter isolate.
Since P. rettgeri and E. cloacae were also resistant to 
amikacin, gentamicin, tobramycin and netilmicin, 16S rRNA 
methyltransferase genes were searched by PCR ampliﬁca-
tion. The 16S rRNA methyltransferase gene armA was iden-
tiﬁed in both isolates (Table 1). Finally, all isolates showed 
resistance to ﬂuoroquinolones.
Taking into account the diversity of multidrug-resistant 
isolates, and their respective phenotypic and molecular 
resistance patterns, the patient was treated with a combi-
nation of colistin, ceftazidime–avibactam with aztreonam, 
and metronidazole for 12 days. Ceftazidime–avibactam in 
addition with aztreonam has been shown to be efficient 
in vitro against metallo-β-lactamase producers despite 
being resistant to ceftazidime–avibactam alone. Sub-
sequently, a regrading inflammation and a progressive 
wound healing of the patient was observed.
This report highlights several issues. As well admitted 
now, antibiotic resistance does not recognize any national 
border. Globalization, trade, and tourism lead altogether 
to a rapid and worldwide spread of resistant micro-organ-
isms. Therefore, it is mandatory to screen for multidrug-
resistant bacteria and multiple of those resistant bacteria 
in patients being hospitalized abroad, to rapidly implement 
the adequate hygiene and infection control measures, and 
consequently prevent further nosocomial spread.
It is well known that NDM producers are endemic in 
India and the Middle East. The Indian subcontinent rep-
resents a huge and growing reservoir of multiple resistant 
bacteria. In addition, the emergence of resistance deter-
minants to conferring resistance to all available amino-
glycosides (namely the 16S rRNA methylases) has been 
already highlighted in Switzerland [10]. This additional 
resistance trait is often associated with carbapenemases 
of the NDM type and shall be systematically searched 
for, since aminoglycosides together with β-lactams and 
ﬂuoroquinolones remain the main antibiotics for treating 
Gram-negative infections. Even though some therapeutical 
options may remain against such NDM-producing strain, 
particularly fosfomycin, nitrofurantoin, colistin [11], this 
report highlights the threat of pandrug resistance in Gram-
negatives, even in Switzerland, is not far.
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Table 1  Resistance 
determinants of the six Gram-
negative bacterial isolates
C patient colonized, C + I patient colonized and infected (rectal abscess)
Strain β-lactamase resistance determinant Non 
β-lactamase 
resistance 
determinant
Carbapenemase ESBL Cephalosporinase 16S rRNA 
methytrans-
ferase
E. coli (C + I) NDM-5 CTX-M-15 – –
K. pneumoniae (C + I) – CTX-M-15 – –
P. rettgeri (C) NDM-5 – CMY ArmA
E. cloacae (C) NDM-1 CTX-M-15 – ArmA
P. aeruginosa (C) VIM-2 – – –
A. baumannii (C + I) NDM-1 – – –
2
htt
p:/
/do
c.r
ero
.ch
Compliance with ethical standards 
Conflict of interest None to declare.
Informed consent All the authors agreed on the submitted version of 
the manuscript.
References
 1. ecdc.europa.eu [Internet]. ECDC/EMEA Joint Technical Report. 
The bacterial challenge: time to react. c2019. https ://ecdc.europ 
a.eu/sites /porta l/ﬁles /media /en/publi catio ns/Publi catio ns/0909_
TER_The_Bacte rial_Chall enge_Time_to_React .pdf. Accessed 16 
Jan 2019.
 2. swissnoso.ch [Internet]. National Centre for Infections prevention; 
c2019. https ://www.swiss noso.ch/en/what-is-it-about /healt hcare 
-assoc iated -infec tions /. Accessed 10 Jan 2019.
 3. Gasser MZ, Cassini W, Kronenberg A. Attributable deaths and 
disability-adjusted life-years caused by infections with antibiotic-
resistant bacteria in Switzerland. Lancet Infect Dis. 2019;19:17–8.
 4. European Committee on Antimicrobial Susceptibility Testing. 
2019. Breakpoint tables for interpretation of MICs and zone diam-
eters. Version 9.0. https ://www.eucas t.org/ﬁlea dmin/src/media /
PDFs/EUCAS T_ﬁles /Break point _table s/v_9.0_Break point _Table 
s.pdf.
 5. Nordmann P, Poirel L, Dortet L. Rapid detection of carbap-
enemase-producing Enterobacteriaceae. Emerg Infect Dis. 
2012;18:1503–7.
 6. Dortet L, Poirel L, Nordmann P. Rapid detection of carbap-
enemase-producing Pseudomonas spp. J Clin Microbiol. 
2012;50:3773–6.
 7. Dortet L, Poirel L, Errera C, Nordmann P. CarbAcineto NP test for 
rapid detection of carbapenemase-producing Acinetobacter spp. J 
Clin Microbiol. 2014;52:2359–64.
 8. Nordmann P, Jayol A, Poirel L. Rapid detection of poly-
myxin resistance in Enterobacteriaceae. Emerg Infect Dis. 
2016;22:1038–43.
 9. Nordmann P, Dortet L, Poirel L. Rapid detection of extended-
spectrum β-lactamase-producing Enterobacteriaceae. J Clin 
Microbiol. 2012;50:3016–22.
 10. Mancini S, Poirel L, Tritten ML, Lienhard R, Bassi C, Nordmann 
P. Emergence of an MDR Klebsiella pneumoniae ST231 produc-
ing OXA-232 and RmtF in Switzerland. J Antimicrob Chemother. 
2018;73:821–3.
 11. Chibabhai V, Nana T, Bosman N, Thomas T, Lowman W. Were 
all carbapenemases created equal? Treatment of NDM-producing 
extensively drug-resistant Enterobacteriaceae: a case report and 
literature review. Infection. 2018;46:1–13.
3
htt
p:/
/do
c.r
ero
.ch
